A detailed history of Regency Capital Management Inc.\De transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Regency Capital Management Inc.\De holds 667,311 shares of AURA stock, worth $5.47 Million. This represents 3.6% of its overall portfolio holdings.

Number of Shares
667,311
Previous 765,055 12.78%
Holding current value
$5.47 Million
Previous $5.78 Million 2.8%
% of portfolio
3.6%
Previous 4.12%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$6.9 - $10.36 $674,433 - $1.01 Million
-97,744 Reduced 12.78%
667,311 $5.95 Million
Q2 2024

Aug 20, 2024

SELL
$6.81 - $7.89 $136,751 - $158,439
-20,081 Reduced 2.56%
765,055 $5.78 Million
Q1 2024

May 07, 2024

BUY
$7.09 - $9.24 $568,348 - $740,696
80,162 Added 11.37%
785,136 $6.16 Million
Q4 2023

Jan 23, 2024

BUY
$7.02 - $11.98 $1.25 Million - $2.13 Million
177,996 Added 33.78%
704,974 $6.25 Million
Q3 2023

Nov 02, 2023

SELL
$8.97 - $12.38 $48,034 - $66,294
-5,355 Reduced 1.01%
526,978 $4.73 Million
Q2 2023

Aug 01, 2023

SELL
$8.51 - $13.33 $96,520 - $151,188
-11,342 Reduced 2.09%
532,333 $6.57 Million
Q1 2023

May 08, 2023

SELL
$8.88 - $12.11 $94,225 - $128,499
-10,611 Reduced 1.91%
543,675 $5.05 Million
Q4 2022

Jan 26, 2023

BUY
$9.86 - $14.59 $3.25 Million - $4.81 Million
329,732 Added 146.84%
554,286 $0
Q3 2022

Nov 04, 2022

SELL
$13.1 - $20.34 $393,890 - $611,583
-30,068 Reduced 11.81%
224,554 $4.07 Million
Q2 2022

Aug 03, 2022

BUY
$12.37 - $21.86 $3.15 Million - $5.57 Million
254,622 New
254,622 $3.61 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $240M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Regency Capital Management Inc.\De Portfolio

Follow Regency Capital Management Inc.\De and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regency Capital Management Inc.\De, based on Form 13F filings with the SEC.

News

Stay updated on Regency Capital Management Inc.\De with notifications on news.